Bivalent Wnt Surrogate Molecules for Fzd–LRP5/6 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for binding moieties that specifically interact with Frizzled (Fzd) and Low-density lipoprotein receptor-related proteins 5 and 6 (LRP5/6) to modulate Wnt signaling pathways, which are complex due to the existence of multiple Wnt ligands and receptors, and the broad expression of LRP5/6 in various tissues.
Innovation Solution
Development of soluble, bivalent, bispecific Wnt surrogate molecules that include regions specifically binding to Fzd receptors and LRP5/6, utilizing antigen-binding fragments such as IgG, scFv, Fab, and VHH or sdAb, to modulate Wnt signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple Wnt ligands and Wnt receptors (Frizzled 1-10) are used to modulate Wnt signaling, then the signaling pathway can be activated, but the complexity of the system increases and specific binding becomes difficult to achieve
Solution Approach 1:
The patent combines multiple binding functions into a single bivalent molecule that simultaneously binds to both Frizzled receptors and LRP5/6 co-receptors. This merging of binding specificities resolves the complexity issue by providing a unified therapeutic agent that targets the complete Wnt signaling complex rather than requiring separate agents for each receptor type.
Solution Approach 2:
The bivalent Wnt surrogate molecule is designed with universal applicability to multiple Wnt signaling components. It can bind to various Frizzled subtypes and both LRP5 and LRP6 co-receptors, making it a multi-functional agent that activates Wnt signaling across different tissue types and pathological conditions without requiring tissue-specific customization.
2Adaptability or versatility
If LRP5/6 co-receptors are used broadly expressed in various tissues, then Wnt signaling can be activated in multiple tissues, but achieving tissue-specific modulation becomes difficult
Solution Approach 1:
The patent employs local quality by making the binding properties of different regions of the bivalent molecule tissue-specific. The Frizzled-binding region can be engineered to preferentially bind to Frizzled subtypes that are enriched in specific tissues (e.g., FZD1 in bone, FZD7 in liver), while the LRP5/6-binding region provides broad tissue coverage. This creates local specificity within the overall versatile molecule.
Solution Approach 2:
The bivalent molecule exhibits asymmetric binding characteristics where one binding region (Frizzled) provides tissue-selective targeting while the other region (LRP5/6) provides broad co-receptor engagement. This asymmetric design allows the molecule to achieve both tissue versatility through LRP5/6 broad expression and tissue specificity through Frizzled subtype preference in a given tissue context.
3Reliability
If bivalent bisspecific molecules are designed to bind both Fzd and LRP5/6, then Wnt signaling activation is enhanced, but the molecular complexity and manufacturing difficulty increase
Solution Approach 1:
The patent uses antibody technology as an intermediary to simplify the manufacturing of bivalent molecules. By utilizing well-established antibody expression systems, purification protocols, and formulation technologies, the complex bivalent structure can be produced using existing pharmaceutical manufacturing infrastructure rather than requiring entirely new manufacturing approaches.
Solution Approach 2:
The patent optimizes manufacturing parameters by adjusting the valency ratio (e.g., 2:1 or 1:1 Fzd:LRP5/6 binding sites), the length and composition of linker regions between binding domains, and the choice of antibody formats (IgG, Fab, scFv). These parameter changes allow optimization of both binding efficacy and manufacturability, enabling production in standard mammalian cell expression systems with conventional purification methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Wnt surrogate molecules effectively activate or increase Wnt signaling, providing therapeutic benefits in treating conditions like osteoporosis, liver regeneration, and various tissue injuries by enhancing Wnt pathway activity.
Implementation Method 1
one or more regions that specifically binds to one or more Frizzled (Fzd) receptor (a Fzd binding region); and one or more regions that specifically binds to a Low-density lipoprotein (LDL) receptor-related protein 5 (LRP5) and/or a Low-density lipoprotein (LDL) receptor-related protein 6 (LRP6)
Data Source
AI summary
The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.